SCHEMBL3575712

SCHEMBL3575712

CCOC(=O)c1cc2cc(-c3ccc(OC(C)C)cc3)ccc2n1-c1ccc(OC(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
THRB P10828 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
MCL1 Q07820 1/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
PKM P14618 1/20 0.38
ATM Q13315 1/20 0.37
CHRNA7 P36544 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3581409 0.95 PTGES (0.59) PTGESMAPTNPSR1ALDH1A1CHRNA7
SCHEMBL3578959 0.93 PTGES (0.77) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL3574312 0.89 PTGES (0.53) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL3577515 0.89 PTGES (0.53) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL3001458 0.89 PTGES (0.51) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL3577805 0.89 PTGES (0.53) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL3578734 0.88 PTGES (0.50) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL2997482 0.88 PTGES (0.50) PTGESSMN1; SMN2POLBMAPTTP53
SCHEMBL5265086 0.86 NOD2 (0.49) PTGESSMN1; SMN2MAPTTP53THRB
SCHEMBL4920933 0.86 PTGES (0.48) PTGESSMN1; SMN2POLBMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705023-B2 Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2010-04-27 US disclosed
EP-1778632-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2008-08-20 EP disclosed
US-20070287715-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2007-12-13 US disclosed
EP-1778632-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-05-02 EP disclosed
WO-2005123673-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287715-A1 Indoles Useful in the Treatment of Inflammation PTGS1, IDO1, PTGES PTGES 3/4885SMN1; SMN2 4318/4885POLB 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.